Psilocybin has been suggested as a novel, rapid-acting treatment for depression. Two consecutive doses have been shown to markedly decrease symptom severity in an open-label setting or when compared to a waiting list group. To date, to our knowledge, no other trial compared a single, moderate dose of psilocybin to a placebo condition. In this double-blind, randomised clinical trial, 52...
We wish to provide a correction of the colour representation of Fig. 2 in order to harmonise the colours representing the Psilocybin and the Placebo condition with the corresponding figure caption and with the colour codes from all other figures across the manuscript. Fig. 2 now depicts the Psilocybin condition in blue and the Placebo condition in yellow. The error occurred as a result of an...
Visual illusions and hallucinations are hallmarks of serotonergic hallucinogen-induced altered states of consciousness. Although the serotonergic hallucinogen psilocybin activates multiple serotonin (5-HT) receptors, recent evidence suggests that activation of 5-HT2A receptors may lead to the formation of visual hallucinations by increasing cortical excitability and altering visual-evoked...